Transverse myelitis associated with *Mycoplasma pneumoniae* infection

P I MACFARLANE AND V MILLER

*Booth Hall Children's Hospital, Manchester*

**SUMMARY** A case of acute transverse myelitis associated with respiratory infection by *Mycoplasma pneumoniae* is described. Circulating antibodies to myelin were detected suggesting that mycoplasma related neurological damage is mediated by producing an immunological myelopathy.

Neurological complications of infection with *Mycoplasma pneumoniae* have affected the meninges, cerebellum, cerebrum, spinal cord, and nerve roots. The pathogenesis of the neurological disorder is uncertain. Evidence suggests an immunological mechanism acting against myelin and nerve cells.

We report on a child with acute transverse myelitis and aseptic meningitis. There was evidence of production of *M pneumoniae* antibody in the blood but no evidence of local antibody synthesis in cerebrospinal fluid (CSF). Antibodies to myelin were shown in blood.

**Case report**

A 14 year old girl presented 10 days after onset of rhinorrhoea, cough, and intermittent pyrexia. Two days before admission she had developed ascending paraesthesia and numbness in both legs. This progressed to total paraplegia. Abnormal clinical findings were confined to the nervous system. She showed mild meningism but was fully conscious. The functions of the cranial nerves, cerebellum, and arms were normal. A complete flaccid paraplegia with areflexia and bilateral extensor plantar responses was noted in her legs as was loss of sensation up to her mid abdomen (level T9–10). Her bladder was palpable. Position and vibration sense was absent in both legs. A chest radiograph showed patchy consolidation in the left lower lobe of the lungs. An extrinsic compressive cord lesion was excluded by myelography.

CSF collected during the procedure contained 50 leucocytes/μl (30% polymorphs, 70% monocytes). A low CSF glucose concentration (2.4 mmol/l (43 mg/100 ml)), blood glucose 6.3 mmol/l (114 mg/100 ml) and raised protein concentration (1.3 g/l) were noted. CSF was sterile. An initial blood film showed considerable autoagglutination of red cells and total white cell count of 12.5 × 10⁹/l (82% neutrophils, 15% lymphocytes, 3% monocytes). Mycoplasma related acute transverse myelitis was provisionally diagnosed.

Treatment was started with erythromycin and prednisolone. Bladder catheterisation and rectal washouts were required. Over the first 48 hours the
sensory loss progressed upwards to mid thoracic level (T4) but then regressed. Leg power began to return on the fifth day in hospital. Spontaneous micturition returned by three weeks. By four weeks return on the fifth day in hospital. Spontaneous neurological function was normal. She was able to walk with help. Two months after illness had resolved, she could walk without help.

The Table shows the results of sequential investigations. Serum antibody titres to cytomegalovirus, influenza A and B, orthomyxovirus A and B, adenovirus, respiratory syncytial virus, and chlamydia yielded normal results. Measles, mumps, varicella, and rubella viruses were not isolated from viral cultures of nasopharyngeal secretions, faeces, urine, or CSF. A monospot for glandular fever was negative. A specific culture medium for mycoplasma was not available. Serum cold agglutinin titres, which were initially high, fell during recovery. Antibody titres to *M. pneumoniae* increased during convalescence. CSF mycoplasma antibody was present to a titre of 1:4. The IgG index, which is an indicator of total CSF IgG, was marginally raised (0.76, normal 0.7). The ratio of serum to albumin concentration in CSF was low (45:1, normal 200:1), indicating that the barrier between blood and CSF was not intact. The mycoplasma antibody present in CSF was probably a reflection of 'leakiness' rather than true intraspinal antibody synthesis.

Strongly positive serum antibodies to spinal myelin (titre of 1:60, control 1:10) and cerebellar myelin (1:40) were detectable by indirect immunofluorescence techniques using delipidated nervous tissue from rats. Antimyelin antibodies were not detectable in CSF.

**Discussion**

Mycoplasma infection was diagnosed on the basis of prodromal symptoms, radiological pulmonary signs, and cold agglutinin production even before serological confirmation became available. Cold agglutinins, though suggestive of mycoplasma infection, are not diagnostic and have been shown in other viral pneumonias. Acute transverse myelitis seems to be a rare form of mycoplasma related neurological disease. The low CSF glucose concentration noted in our patient has been reported in some other cases.

Although antibodies to *M. pneumoniae* have been reported to be present in the CSF of two other patients with this condition,1,4 the integrity of the barrier between blood and CSF was not reported. The abnormally low ratio of serum to albumin concentration in CSF in our patient suggests that antibody in the CSF was detectable because of leakage from serum rather than by synthesis within the spinal cord or CSF. There has been only one previous report giving evidence of direct invasion of the central nervous system by *M. pneumoniae*.5

Antibodies to myelin were present in the serum of our patient. This supports the hypothesis that mycoplasma related neurological damage is mediated by producing an immunological myelopathy. Antibodies induced by mycoplasma infection are known to cross react not only with human erythrocyte I antigen (producing the cold agglutinin effect) but also with other tissues including that of the brain.6 It is not possible to say whether the use of steroids had any beneficial effect on these immunological mechanisms. Neither has the use of plasmapheresis to remove antimyelin antibodies, as proposed by Cotter et al,4 been proved to be beneficial.

Erythromycin is effective in treating mycoplasma respiratory infection but it is not known whether the drug alters the neurological course of infection. As evidence suggests an immunological mechanism rather than direct invasion, the poor penetrability of erythromycin into the CSF may not be a disadvantage in this respect.

**References**


<table>
<thead>
<tr>
<th>Day in hospital</th>
<th>Erythrocyte sedimentation rate (mm in first hour)</th>
<th>Serum cold agglutinin titres</th>
<th>Serum mycoplasma titres</th>
<th>Cerebrospinal fluid mycoplasma titres</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>33</td>
<td>1:64</td>
<td>1:512</td>
<td>1:160</td>
</tr>
<tr>
<td>9</td>
<td>8</td>
<td>1:8</td>
<td>1:128</td>
<td>nd</td>
</tr>
<tr>
<td>16</td>
<td>nd</td>
<td>negative</td>
<td>1:64</td>
<td>nd</td>
</tr>
<tr>
<td>23</td>
<td>nd</td>
<td>negative</td>
<td>1:64</td>
<td>nd</td>
</tr>
<tr>
<td>30</td>
<td>9</td>
<td>negative</td>
<td>1:32</td>
<td>nd</td>
</tr>
</tbody>
</table>

nd indicates not done.
82 MacFarlane and Miller

Prophylactic ethamsylate for periventricular haemorrhage

R W I COOKE AND M E I MORGAN

Regional Neonatal Intensive Care Unit, University of Liverpool, Liverpool Maternity Hospital, Liverpool

SUMMARY Drug prophylaxis with ethamsylate for periventricular haemorrhage in very low birthweight infants significantly reduced the incidence of periventricular haemorrhage in survivors. A reduction in abnormalities at follow up and in insertion of ventriculoperitoneal shunts was also noted.

Although there has been a rapid increase in survival of very low birthweight infants requiring intensive care, neurodevelopmental sequelae remain a problem in some. Improvements in non-invasive techniques for imaging the neonatal brain have made it possible to diagnose periventricular haemorrhage (PVH) and some ischaemic lesions in vivo. The association of PVH with neurodevelopmental sequelae at follow up is well documented. Drug prophylaxis of PVH with phenobarbitone or ethamsylate has been claimed to reduce the incidence of PVH on ultrasound examination, but no information on outcome is available. We report follow up data in a group of ventilated infants of very low birthweight treated prophylactically with ethamsylate during a 2 year period and compare these infants with a similar group of untreated infants admitted during the same period.

Patients and methods

A double blind, randomised, placebo controlled trial of ethamsylate prophylaxis of PVH was carried out at this hospital in 1980–1, and the results were published elsewhere. For the following 6 months no effective prophylaxis was given, and at a later date open use of ethamsylate began (in all ventilated infants <1500 g). To have enough infants to form a follow up study, all very low birthweight infants admitted to the unit over a two year period were considered, whether they were included in the original trial or not. Only infants born in this hospital and weighing 501–1500 g at birth; who were free from PVH on initial ultrasound examination; ventilated for at least 6 hours; free from lethal congenital malformations, meningitis, or Down's syndrome; and who survived to be followed up for at least one year were included. Forty three such infants had been treated with ethamsylate 12.5 mg/kg 6 hourly for 16 doses beginning within two hours of birth. Forty eight had not been treated with ethamsylate and formed the control group. Table 1 gives clinical data for the group receiving treatment and for the controls.

Follow up examinations were performed at this unit at regular intervals, except in a few cases where for social or economic reasons follow up examination had to be performed at the referring district hospital. All infants were followed for between one and three years and were assessed, as appropriate, by neurological examination, Denver Developmental Screening test, and Stycar tests of hearing and vision. Infants identified as having abnormalities were referred for specialist developmental, ophthal-
Transverse myelitis associated with Mycoplasma pneumoniae infection.

P I MacFarlane and V Miller

Arch Dis Child 1984 59: 80-82
doi: 10.1136/adc.59.1.80

Updated information and services can be found at:
http://adc.bmj.com/content/59/1/80

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/